Global Lysosomal Acid Lipase Deficiency (LAL-D) Market, By Type (Early Onset Wolman Disease and Late onset CESD), Treatment (Enzyme Replacement Therapy, Lipid-Modifying Agents (Statins), Surgery, Stem Cell Transplantation, Supportive Care), Route of Administration (Oral, Parenteral, Others), End-Users (Clinics, Hospitals, Ambulatory Surgical Centre, Others), Distribution Channel (Direct Tender, Retail Pharmacy, Hospital Pharmacy, Others) – Industry Trends and Forecast to 2030.
Lysosomal Acid Lipase Deficiency (LAL-D) Market Analysis and Size
Lysosomal acid lipase deficiency (LAL-D), also known as wolman disease or cholesteryl ester storage disease (CESD), is a rare genetic disorder characterized by a deficiency of the lysosomal acid lipase enzyme. This enzyme plays a crucial role in breaking down fats and cholesterol in the body. When it is deficient or nonfunctional, it leads to the accumulation of lipids (fats) in various tissues and organs, causing a wide range of symptoms and health complications. Advances in diagnostic tools and genetic testing have made it easier to identify and confirm cases of LAL-D. Early and accurate diagnosis is crucial for managing the condition effectively. Over the years, there has been a significant increase in awareness about rare diseases such as LAL-D among healthcare professionals, patients, and the general public. This heightened awareness has led to more accurate diagnosis and treatment of the condition.
Data Bridge Market Research analyses that the (LAL-D) market which was USD 612.00 million in 2022, and is expected to reach upto USD 1,311.88 million by 2030, and is expected to undergo a CAGR of 10.0% during the forecast period. This indicates that the market value. “Early Onset Wolman Disease” dominates the type segment of the lysosomal acid lipase deficiency (LAL-D) market owing to increasing pharmaceutical and biopharmaceutical companies investing in the preclinical screening activities which are helping them in the late-stage failures and for the development of therapeutics segment. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Lysosomal Acid Lipase Deficiency (LAL-D) Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Early Onset Wolman Disease and Late onset CESD), Treatment (Enzyme Replacement Therapy, Lipid-Modifying Agents (Statins), Surgery, Stem Cell Transplantation, Supportive Care), Route of Administration (Oral, Parenteral, Others), End-Users (Clinics, Hospitals, Ambulatory Surgical Centre, Others), Distribution Channel (Direct Tender, Retail Pharmacy, Hospital Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E., Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa
|
|
Market Players Covered
|
Alexion Pharmaceuticals, Inc. (U.S.), Pfizer Inc. (U.S.), Morepen (India), LUPIN (India), Triveni Interchem Private Limited (India), Lannett (U.S.), Hetero Healthcare Limited (India), Sun Pharmaceutical Industries Ltd. (India), Zydus Cadila (India), Sandoz International GmbH (Germany), BioCrick BioTech (China), Actiza Pharmaceutical Private Limited (India), Teva Pharmaceuticals USA, Inc. (U.S.), Glenmark Pharmaceutical Inc.(India), ANGLE BIO PHARMA (India), Accord Healthcare Limited (India), AstraZeneca (U.K.), Prudence Pharma Chem (India), Novadoz Pharmaceuticals (U.S.), Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (U.S.), Perrigo Company plc (Ireland)
|
|
Market Opportunities
|
|
Market Definition
Lysosomal acid lipase deficiency (LAL-D) market is the commercial and healthcare ecosystem related to the diagnosis, treatment, and management of lysosomal acid lipase deficiency, also known as wolman disease or cholesteryl ester storage disease (CESD). LAL-D is a rare genetic disorder characterized by a deficiency of the lysosomal acid lipase enzyme, which plays a crucial role in breaking down fats and cholesterol in the body. When this enzyme is deficient or nonfunctional, it leads to the accumulation of lipids (fats) in various tissues and organs, causing a wide range of symptoms and health complications.
Global Lysosomal Acid Lipase Deficiency (LAL-D) Market Dynamics
Drivers
- Advancements in Diagnostic Technologies
Advances in diagnostic tools and genetic testing have made it easier to diagnose LAL-D. More accurate and accessible diagnostic methods enable earlier identification of affected individuals, which is crucial for timely intervention.
- Patient Advocacy and Support
Patient advocacy groups and foundations dedicated to LAL-D raise awareness, provide support to affected individuals and their families, and actively promote research. Their efforts help drive interest and investment in finding effective treatments.
Opportunity
- Evolving Healthcare Landscape
Changes in healthcare systems, such as an increased focus on rare diseases, personalized medicine, and precision diagnostics, contribute to the growth of the LAL-D market. Healthcare providers are better equipped to diagnose and manage rare diseases such as LAL-D.
Moreover, the demand for lysosomal acid lipase deficiency (LAL-D) is not only limited to developed countries but is also being witnessed in the developing countries which will further act as driver that will lead to the growth of the lysosomal acid lipase deficiency (LAL-D) market in the above mentioned projected timeframe.
Restraint/Challenge
- Long Development Timelines
Developing treatments for rare diseases often involves lengthy research and development timelines, including clinical trial phases. This can delay the availability of therapies for patients who urgently need them.
Recent Developments
- Currently, Alexion Pharma’s Kanuma is the only product approved for LAL-D treatment. Kanuma (sebelipase alfa) is a subcutaneously delivered enzyme replacement treatment(ERT) approved in the EU (September 2015), U.S. (December 2015), and Japan (March 2016) for LAL-D patients
- In addition, the CESD cohort is prescribed statins and other nutritional supplements. Pfizer (Lipitor) and Merck (Zetia) are key players in the statins segment of the CSED market. However, these companies are poised to lose market share on account of significant competition from generics and approval of ERT for both early and late-onset types of this disease. Unmet needs within the LAL-D space present a strong opportunity to develop novel first-in-class therapies
Global Lysosomal Acid Lipase Deficiency (LAL-D) Market Scope
The lysosomal acid lipase deficiency (LAL-D) market is segmented on the basis of type, treatment, route of administration, end-users, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Early Onset Wolman Disease
- Late onset CESD
Treatment
- Enzyme Replacement Therapy
- Lipid-Modifying Agents (Statins)
- Surgery
- Stem Cell Transplantation
- Supportive Care
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Clinics
- Hospitals
- Ambulatory Surgical Centre
- Others
Distribution Channel
- Direct Tender
- Retail Pharmacy
- Hospital Pharmacy
- Others
Global Lysosomal Acid Lipase Deficiency (LAL-D) Market Regional Analysis/Insights
The lysosomal acid lipase deficiency (LAL-D) market is analysed and market size insights and trends are provided by type, treatment, route of administration, end-users, and distribution channel as mentioned above.
The countries covered in the lysosomal acid lipase deficiency (LAL-D) market report are U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E., Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa
North America is expected to dominate the lysosomal acid lipase deficiency (LAL-D) market due to rise in the presence of key players and increased funding from public and private entities have augmented drug discovery and development and rise in the volume of expenditure carried out for advancing the technologies available for development of pharmaceuticals in this region.
Asia-Pacific is expected to grow at the highest growth rate during the forecast period of 2023 to 2030 due to rise in the availability of numerous advanced technologies utilized for protein binding in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and up-stream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The lysosomal acid lipase deficiency (LAL-D) market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for lysosomal acid lipase deficiency (LAL-D) market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the lysosomal acid lipase deficiency (LAL-D) market. The data is available for historic period 2015 to 2020.
Competitive Landscape and Lysosomal Acid Lipase Deficiency (LAL-D) market Share Analysis
The lysosomal acid lipase deficiency (LAL-D) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the company's focus related to lysosomal acid lipase deficiency (LAL-D) market.
Some of the major players operating in the lysosomal acid lipase deficiency (LAL-D) market are:
- Alexion Pharmaceuticals, Inc. (U.S.)
- Pfizer Inc. (U.S.)
- Morepen (India)
- LUPIN (India)
- Triveni Interchem Private Limited (India)
- Lannett (U.S.)
- Hetero Healthcare Limited (India)
- Sun Pharmaceutical Industries Ltd.(India)
- Zydus Cadila (India)
- Sandoz International GmbH (Germany)
- BioCrick BioTech (China)
- Actiza Pharmaceutical Private Limited (India)
- Teva Pharmaceuticals USA, Inc. (U.S.)
- Glenmark Pharmaceutical Inc. (India)
- ANGLE BIO PHARMA (India)
- Accord Healthcare Limited (India)
- AstraZeneca (U.K.)
- Prudence Pharma Chem (India)
- Novadoz Pharmaceuticals (U.S.)
- Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (U.S.)
- Perrigo Company plc (Ireland)
SKU-